Poster Abstract Session:
078. Zika Virus
Thursday, October 5, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
839
ZIKA-001: Safety and Immunogenicity of an Engineered DNA Vaccine Against ZIKA virus infection
Pablo Tebas, MD, FIDSA; Christine C. Roberts, PhD; Kar Muthumani, PhD; Emma Reuschel, PhD; Scott White, PhD; Amir S. Khan, PhD; Trina Racine, PhD; Hyeree Choi, BS; Faraz Zaidi, BS; Jean Boyer, PhD; Sagar Kudchodkar, PhD; Young K Park, JD; Sylvie Trottier, MD, PhD; Celine Remigio, DPT, RN; Diane Krieger, MD; Gary P. Kobinger, PhD; David Weiner, PhD; Joel Maslow, MD, PhD
Posters
  • IDSA poster (1).pdf (3.0 MB)
  • 840
    Zika Virus Epidemic in the Dominican Republic, 2016
    Farah Peña, MD; Raquel Pimentel, MD; Shaveta Khosla, MPH; Supriya Mehta, MHS, PhD; Maximo Brito, MD, MPH
    841
    Dengue IgG Seropositivity and Zika Viral Load
    Jennifer Read, MD, MS, MPH, DTM&H (FAAP, FIDSA); Luisa I. Alvarado, MD, FAAP; Brenda Torres-Velasquez, PhD; Jorge L. Munoz-Jordan, PhD; Manuela Beltran, MS; Sheila Capre, MD; Laura Adams, DVM MPH; Sanet Torres-Torres, MD; Gilberto Santiago, PhD; Lillian Rivera, MD, FAAP; Aidsa Rivera-Sánchez, MS; Olga D. Lorenzi, MS; Tyler Sharp, PhD; Carlos Garcia-Gubern, MD; Stephen Waterman, MD
    842
    Challenges of Zika Virus Testing in Pregnancy in the Setting of Local Mosquito-Borne Transmission
    Jaclyn Kwal, BA; Michelle Bartlett, BA; Anise Crane, BS; Samantha Greissman, BA, MPH; Naiomi Gunaratne, BS; Meghan Lardy, BS; Michelle Picon, MD; Rebecca Starker, BS; Colette Tse, BS; Patricia Rodriguez, MD; Ivan Gonzalez, MD; Christine Curry, MD, PhD
    843
    Efficacy of Galidesivir against Ebola Virus Disease in Rhesus Monkeys
    Travis Warren, Ph.D.; Steve MacLennan, Ph.D.; Amanda Mathis, Ph.D.; Enzo Giuliano, Ph.D.; Ray Taylor, MBA; William Sheridan, MB BS
    844
    Zika Virus Serologic Diagnosis by NS1 ELISA in Curacao
    Samantha Manuel, Msc; Liane Virginia-Cova, MSc; Loubiela Joseph, MSc; Chris Roggeveen, MD; Radjin Steingrover, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.